Observational studyBMC ophthalmology2026
Visual acuity and retinal thickness outcomes following anti-VEGF therapy in RVO: influence of early vs. delayed treatment.
Observational study in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsRetinal vein occlusion (RVO) is a common cause of vision loss, treated primarily with intravitreal anti-VEGF injections. This study aimed to investigate how the timing of treatment initiation affects visual acuity and retinal thickness outcomes in patients with branch (BRVO) and central retinal vein occlusion (CRVO).
methodsA retrospective observational study was conducted involving 86 patients diagnosed with RVO (54 BRVO, 32 CRVO) and treated with anti-VEGF therapy at a single UK centre. Patients were stratified into early (≤ 28 days) and delayed (> 28 days) treatment groups based on the time from diagnosis to first injection. Visual acuity (ETDRS letters) and central retinal thickness (µm) were recorded at diagnosis, after three loading doses, and at one year. Paired t-tests were used to assess changes over time. Associations between treatment timing and outcomes were evaluated using Spearman’s rank correlation, while between-group comparisons were performed using Mann–Whitney U and chi-square tests.
resultsBRVO patients had significant VA gains at three injections (mean + 13.2 letters, p < 0.001) and at one year (p = 0.0002), while CRVO patients showed a non-significant trend toward improvement (p = 0.081). CRT reductions were significant in both CRVO and BRVO at three injections and at one year (p < 0.001). Earlier treatment (≤ 28 days) was weakly correlated with greater CRT reduction in CRVO (p = 0.047), but no significant association was found between treatment timing and VA change or likelihood of > 15-letter improvement in either group.
conclusionsWhile early treatment led to short-term visual and anatomical gains, long-term visual outcomes at one year were not significantly associated with treatment timing, suggesting other clinical and individual factors contribute to final prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.